NOX1 and Hepatic fibrosis: Currently both NOX1 and NOX4 and CYP2E1 are implicated in development of inflammation and liver fibrosis [4, 33–35], whereas pharmacological inhibitors of these enzymes have been shown in vivo to prevent hepatocyte death and attenuate fibrosis progression [36, 37].